NCT05087680Completed
An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South
Source: ClinicalTrials.gov · Last updated 1 Jul 2026
Brief summary (registry, in English)
Investigators will use a generalized framework for the adaptation of EBIs to inform the development of a brief Acceptance and Commitment Therapy (ACT)-based culturally appropriate pre-exposure prophylaxis (PrEP) intervention tailored to young Black men who have sex with men (YBMSM), named ACTPrEP.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 66 (actual)
- First submitted
- 13 Sept 2021
- Start date
- 14 Sept 2023
- Primary completion date
- 18 Dec 2025
- Lead sponsor
- Rhode Island Hospital
- Diseases
- HIV
- NCT number
- NCT05087680
What you commit to
- Study type: Interventional
- Participants enrolled: 66
- From 14 Sept 2023 to the primary completion date, 18 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participating in another PrEP study
- Unable to provide consent
Who the study is looking for
- English speaking
- Between 18-34 years old
- Male sex assigned at birth
- Identify as African American/Black
- Not enrolled in another PrEP related study
- Able to give consent
- Not taken PrEP in past 3 months
- Report having sex with a man in the past 3 months
- PrEP-eligible according to CDC guidelines
Age in the registry: 18 years to 34 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Univeristy of Mississippi Medical Center Coordinator of this site? Confirm its status | Jackson | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.